Effects of Clofibrate on Salt Loading-Induced Hypertension in Rats
Metadatos
Mostrar el registro completo del ítemAutor
Cruz, Antonio; Rodríguez Gómez, Isabel María; Pérez Abúd, Rocío; Vargas, Miguel Ángel; Wangensteen, Rosemary; Quesada, Andrés; Osuna, Antonio; Moreno, Juan ManuelEditorial
Wiley
Fecha
2010-10-14Referencia bibliográfica
Cruz, Antonio, Rodríguez-Gómez, Isabel, Pérez-Abud, Rocío, Vargas, Miguel Ángel, Wangensteen, Rosemary, Quesada, Andrés, Osuna, Antonio, Moreno, Juan Manuel, Effects of Clofibrate on Salt Loading-Induced Hypertension in Rats, BioMed Research International, 2011, 469481, 8 pages, 2011. https://doi.org/10.1155/2011/469481
Patrocinador
Grant (CTS-1659) from the Department of Innovation, Science, and Business of the Andalusian Regional Government, and from the Carlos III Health Institute of the Spanish Ministry of Health and Consumer Affairs (Red de Investigación Renal, REDinREN RD06/0016/0017); FEDER “Una manera de hacer Europa.”Resumen
The effects of clofibrate on the hemodynamic and renal manifestations of increased saline intake were analyzed. Four groups of male Wistar rats were treated for five weeks: control, clofibrate (240 mg/kg/day), salt (2% via drinking water), and salt + clofibrate. Body weight, systolic blood pressure (SBP), and heart rate (HR) were recorded weekly. Finally, SBP, HR, and morphologic, metabolic, plasma, and renal variables were measured. Salt increased SBP, HR, urinary isoprostanes, NOx, ET, vasopressin and proteinuria and reduced plasma free T4 (FT4) and tissue FT4 and FT3 versus control rats. Clofibrate prevented the increase in SBP produced by salt administration, reduced the sodium balance, and further reduced plasma and tissue thyroid hormone levels. However, clofibrate did not modify the relative cardiac mass, NOx, urinary ET, and vasopressin of saline-loaded rats. In conclusion, chronic clofibrate administration prevented the blood pressure elevation of salt-loaded rats by decreasing sodium balance and reducing thyroid hormone levels.





